Actionable news
All posts from Actionable news
Actionable news in ARWR: Arrowhead Research Corporation,

Cantor Sees 100% Upside for Arrowhead Pharmaceuticals Inc (ARWR) Shares

Cantor analyst Elemer Piros initiated coverage on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), with a Buy rating and price target of $15, which represents a 100% increase from where the shares last closed.

In just two years, the number of people who have found cures from the four drugs approved for hepatitis C is just under 1 million across the globe. Following this success, researches are concentrating efforts to now eradicate the hepatitis B virus (HBV).

Piros thinks ARWR has already revealed significant reduction of viral load and key viral antigens in patients through the firm’s use of interference RNAs...